Trial Profile
A Phase Ia, Multi-centers, Open-label, Dose-escalation Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01 (a Potential Rituximab Biosimilar) in Patients With CD20-positive B-cell Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 18 Jul 2017 New trial record